BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia
US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...
NASDAQ: ONC
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...